With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the chronic kidney disease (CKD) market is forecast to grow at a compound annual growth rate (CAGR) of 19.6% from $2.2 billion in 2023 to $13.5 billion in 2033 across the seven major markets (7MM*), according to GlobalData, a leading data and analytics company.
GlobalData’s latest report “Chronic Kidney Disease: Seven-Market Drug Forecast and Market Analysis,” reveals that the US will contribute the most to the growth of the CKD market due to the higher prevalence of CKD in this market, as well as the substantially higher cost of prescription medications in the country compared with Europe and Japan.
Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “The pressure on pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. Companies are approaching the CKD market with the strategies of optimizing treatment safety and compliance, as well as developing novel drug classes. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has remained relatively consistent, and the use of sodium-glucose transporter 2 inhibitors has become well established for CKD.”
Over the forecast period of 2023–33, GlobalData expects the launches of promising pipeline drugs REACT (rilparencel), Ozempic (semaglutide), zibotentan + dapagliflozin combination, and balcinrenone + dapagliflozin combination to increase market size and further promote growth.
Jaddoo concludes: “It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance. The key opinion leaders interviewed by GlobalData hold mixed views on adding another drug on top of their patients’ complex treatment regimens.
“Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies.”
*7MM – The US, France, Germany, Italy, Spain, the UK, and Japan
